These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Predicting cardiovascular complications after liver transplantation: 007 to the rescue? Liu H; Lee SS Liver Transpl; 2011 Jan; 17(1):7-9. PubMed ID: 21254338 [No Abstract] [Full Text] [Related]
7. Comparison of three different methods of assessing cardiovascular disease risk in New Zealanders with Type 2 diabetes mellitus. Metcalf PA; Wells S; Scragg RK; Jackson R N Z Med J; 2008 Sep; 121(1281):49-57. PubMed ID: 18797484 [TBL] [Abstract][Full Text] [Related]
8. Anthropometric measures in cardiovascular disease prediction: comparison of laboratory-based versus non-laboratory-based model. Dhana K; Ikram MA; Hofman A; Franco OH; Kavousi M Heart; 2015 Mar; 101(5):377-83. PubMed ID: 25502814 [TBL] [Abstract][Full Text] [Related]
9. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials. Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589 [TBL] [Abstract][Full Text] [Related]
11. A consultation-based method is equal to SCORE and an extensive laboratory-based method in predicting risk of future cardiovascular disease. Petersson U; Ostgren CJ; Brudin L; Nilsson PM Eur J Cardiovasc Prev Rehabil; 2009 Oct; 16(5):536-40. PubMed ID: 19357517 [TBL] [Abstract][Full Text] [Related]
12. From hyperglycemia to the risk of cardiovascular disease. Leiter LA Rev Cardiovasc Med; 2006; 7 Suppl 2():S3-9. PubMed ID: 17224875 [TBL] [Abstract][Full Text] [Related]
13. Diabetes mellitus and vascular risk: continuing the quest for the elusive keystone. Marso SP Diab Vasc Dis Res; 2005 Feb; 2(1):7-8. PubMed ID: 16305066 [No Abstract] [Full Text] [Related]
14. Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes. Colette C; Monnier L Horm Metab Res; 2007 Sep; 39(9):683-6. PubMed ID: 17846977 [TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 in the prediction of primary cardiovascular events in diabetes patients: results from the ESTHER study. Herder C; Schöttker B; Rothenbacher D; Roden M; Kolb H; Müller H; Brenner H Atherosclerosis; 2011 May; 216(1):244-7. PubMed ID: 21334625 [TBL] [Abstract][Full Text] [Related]
16. Plasma triglycerides, an independent predictor of cardiovascular disease in men: a prospective study based on a population with prevalent metabolic syndrome. Onat A; Sari I; Yazici M; Can G; Hergenç G; Avci GS Int J Cardiol; 2006 Mar; 108(1):89-95. PubMed ID: 16085325 [TBL] [Abstract][Full Text] [Related]
17. The Framingham Study, diabetes mellitus and cardiovascular disease: turning back the clock. Kengne AP; Turnbull F; MacMahon S Prog Cardiovasc Dis; 2010; 53(1):45-51. PubMed ID: 20620425 [TBL] [Abstract][Full Text] [Related]
18. Reassessment of cardiovascular risk in diabetes. Jaffe JR; Nag SS; Landsman PB; Alexander CM Curr Opin Lipidol; 2006 Dec; 17(6):644-52. PubMed ID: 17095909 [TBL] [Abstract][Full Text] [Related]
19. [Prevention of cardiovascular risk in diabetes]. Marre M; Duval-Leclercq M; Travert F Rev Prat; 2007 Sep; 57(13):1423-30. PubMed ID: 18018541 [TBL] [Abstract][Full Text] [Related]
20. ["Diabetes and cardiovascular diseases"]. Schernthaner G; Hitzenberger G Wien Med Wochenschr; 2010 Jan; 160(1-2):1-2. PubMed ID: 20229154 [No Abstract] [Full Text] [Related] [Next] [New Search]